SENATOR: Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour

Sponsor
The Netherlands Cancer Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03448822
Collaborator
(none)
76
91

Study Details

Study Description

Brief Summary

Assessment of accuracy of sentinel node biopsy, defined as the false negative rate.

Condition or Disease Intervention/Treatment Phase
  • Procedure: sentinel node procedure

Detailed Description

Current practice in patients with Clinical Stage I (CS I) testicular germ cell tumour is active surveillance after orchiectomy, with relapses occurring in 15-20% of patients. The majority of relapses occur in the lymph nodes as lymphogenic spread is the dominant route of dissemination. A sentinel node procedure, in which the sentinel lymph node is resected and pathologically examined, could be more reliable to identify patients who are likely to relapse.

Early identification of patients with micro-metastases in the sentinel node makes it possible to treat these patients at the earliest possible moment. Absence of metastases could lead in the future to a less intensive follow up protocol than the present one.

Study Design

Study Type:
Observational
Anticipated Enrollment :
76 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour
Anticipated Study Start Date :
Sep 1, 2018
Anticipated Primary Completion Date :
Apr 1, 2020
Anticipated Study Completion Date :
Apr 1, 2026

Arms and Interventions

Arm Intervention/Treatment
sentinel node procedure

a robot-assisted laparoscopic sentinel node procedure.

Procedure: sentinel node procedure
a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis

Outcome Measures

Primary Outcome Measures

  1. identify patients witha low risk of cancer recurrenceincluded in current active surveillance protocols. [surgery 1 day, follow up 5 years]

    identify patients who have such a low risk of cancer recurrence that it is not necessary anymore to be included in current active surveillance protocols by removing the sentinal lymph node to check for occult metastasis

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients suspected of testicular germ cell tumour, based on physical examination, ultrasound imaging, and tumour markers

  • Patients 18 years and older

  • No evidence of metastases on first staging (thoraco-abdominopelvic CT)

  • Written and signed informed consent

Exclusion Criteria:
  • Patients with evidence of metastases at first staging

  • Patients with a second primary tumour

  • Patients with recent (< 6 months before diagnosis) surgical treatment to the external genitals or recent surgical intervention in the inguinal or retroperitoneal regions

  • Patients with previous abdominal surgery, necessitating open surgical approach for the sentinel node biopsy

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • The Netherlands Cancer Institute

Investigators

  • Principal Investigator: Simon Horenblas, MD, PhD, NKI-AvL

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The Netherlands Cancer Institute
ClinicalTrials.gov Identifier:
NCT03448822
Other Study ID Numbers:
  • M18TGC
First Posted:
Feb 28, 2018
Last Update Posted:
Aug 22, 2018
Last Verified:
Jan 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2018